Skip to content
777 Sourcing.

Capability

surface plasmon resonance

Suppliers
3
States & provinces
2
Countries
2

3 surface plasmon resonance suppliers across 2 states and provinces in 2 countries. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

ABZYME THERAPEUTICS LLC

POTTSTOWN, PA

Abzyme Therapeutics is a biopharmaceutical discovery and service company located outside Philadelphia, specializing in modular antibody discovery and conditionally-active antibody engineering for immunotherapy using proprietary antibody generation and optimization platforms based on yeast-display, self-diversifying libraries and FACS single-cell sorting. The company has over 60 therapeutic and diagnostic assets in development for infectious diseases, cancer, ophthalmology, inflammation and central nervous system disorders.

affinity maturationantibody discoveryantibody humanizationantibody optimizationbispecific antibody generationELISAFACS single-cell sortingFlow Cytometryimmunohistochemistryllama immunizationWestern blottingyeast display

BIOASCENT

MOTHERWELL

BioAscent is a provider of integrated drug discovery services based at the former Organon/MSD R&D site in Newhouse, Scotland, UK. Founded in 2013, its services include assay development, target analysis, compound screening, medicinal and synthetic chemistry, computational chemistry, DMPK, protein science and compound management, with access to in-house diversity and fragment libraries.

assay developmentbiophysicscompound managementcompound screeningcompound storage and logisticscomputational chemistryDMPKhigh throughput screeningin silico discoveryLC-MSliquid handlingmedicinal chemistryNMRprotein productionpurificationstructural biologysynthetic chemistry

FOR-ROBIN INC

BUFFALO, NY

For-Robin, Inc, founded in 2012, is an antibody immunotherapy company named in honor of the founder's sister who died at age 31 of breast cancer. Its proprietary monoclonal antibody JAA-F11 and humanized variants (hJAA-F11) target breast and lung cancer cell subtypes including triple negative breast cancer. The company is preparing an IND for lung cancer imaging in collaboration with the NCI NExT program, with clinical imaging trials planned.

ADCC assaysantibody production and purificationCDC assayscytotoxicity assaysenzyme immunoassaysFlow Cytometryimmunotherapymolecular cloningradioimmuno-localization

Related capabilities

Other processes offered by the shops that list surface plasmon resonance.

Browse all capabilities